TDF-FTC before and after sex reduced HIV infection but increased GI, renal events in men who have sex with men
Authors: Dennis G. Maki
Journal: Annals of Internal Medicine (2016)

ACP Journal Club15 March 2016TDF-FTC before and after sex reduced HIV infection but increased GI, renal events in men who have sex with menDennis G. Maki, MD, MACPDennis G. Maki, MD, MACPUniversity of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA (D.G.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2016-164-6-028 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationMolina JM, Capitant C, Spire B, et al; ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237-46. https://pubmed.ncbi.nlm.nih.gov/26624850Clinical Impact RatingsGIM/FP/GP: Infectious Disease: References1 Okwundu CI, Uthman OA, Okoromah CA. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev. 2012;7:CD007189. [PMID: 22786505] Google Scholar2 McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015 Sep 9. [Epub ahead of print] [PMID: 26364263] Google Scholar3 Centers for Disease Control and Prevention (CDC). Preexposure prophylaxis for the prevention of HIV infection in the United States—2014. A clinical practice guideline. MMWR Morbid Mortal Weekly Rep. 2012;61:586-9. Google Scholar4 WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2013 June. pp 1-78. www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/ (accessed January 4, 2015). Google Scholar5 Walensky RP, Jacobsen MM, Bekker LG, et al. Potential clinical and economic value of long-acting preexposure prophylaxis for South African women at high-risk for HIV infection. J Infect Dis. 2015 Dec 17. [Epub ahead of print] [PMID: 26681778] Google Scholar6 Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep. 2007;4:165-72. [PMID: 18366947] Google Scholar7 Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156:541-50. [PMID: 22508731] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA (D.G.M.)This article was published at Annals.org on 1 March 2016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 March 2016Volume 164, Issue 6Page: JC28KeywordsAdverse eventsHIVHIV infectionsHIV preventionHIV-1Human sexual behaviorMale male sexual contactPopulation statisticsPreexposure prophylaxisSafety ePublished: 15 March 2016 Issue Published: 15 March 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...